Sero-Reactivity to Microbial Components in Crohn's Disease Is Associated with Disease Severity and Progression, but not NOD2/CARD15 Genotype
- 1 December 2004
- journal article
- Published by Wolters Kluwer Health in American Journal of Gastroenterology
- Vol. 99 (12) , 2376-2384
- https://doi.org/10.1111/j.1572-0241.2004.40417.x
Abstract
Antibodies directed against the porin protein C of Escherichia coli (anti-OmpC) and Pseudomonas fluorescens (anti-I2) have recently been described in Crohn's disease (CD). Those directed against Saccharomyces cerevisiae (ASCA) and the perinuclear component of neutrophils (pANCA) have been more widely studied and may be of diagnostic importance. We aimed to assess the frequency of anti-OmpC, anti-I2, ASCA, and pANCA, in an independent Scottish CD cohort, establish phenotypic associations, and compare with a U.S. cohort. One hundred and forty-two well-characterized CD patients (76 females, median age 39 yr (17–88)) were studied. CD was classified by the Vienna classification. Sera were assayed for anti-OmpC, anti-I2, ASCA, and pANCA. Allele specific primers were used for NOD2/CARD15 genotyping. Anti-OmpC, anti-I2, ASCA, and pANCA were present in sera from 37%, 52%, 39%, and 14% of CD patients, respectively. Multivariate analysis demonstrated independent associations of anti-OmpC to be progression of disease type (p= 0.005) and long disease duration (p= 0.002), and those of anti-I2 to be long disease duration (p= 0.002) and the need for surgery (p= 0.033). ASCA were associated with disease progression (p < 0.001). When the presence and magnitude of all antibody responses were considered, reactivity to microbial components was associated with long disease duration (p < 0.001), progression of disease type (p < 0.001), penetrating disease (p= 0.008), small bowel disease (p < 0.02), and the need for surgery (p < 0.001). There was no association of antibody status to NOD2/CARD15 genotype. Reactivity to microbial components is associated with severe CD characterized by small bowel involvement, frequent disease progression, longer disease duration, and greater need for intestinal surgery.Keywords
This publication has 47 references indexed in Scilit:
- The immunological and genetic basis of inflammatory bowel diseaseNature Reviews Immunology, 2003
- Prophylaxis of pouchitis onset with probiotic therapy: a double-blind, placebo-controlled trialGastroenterology, 2003
- Nod2 Is a General Sensor of Peptidoglycan through Muramyl Dipeptide (MDP) DetectionJournal of Biological Chemistry, 2003
- Genetics of inflammatory bowel disease: scientific and clinical implicationsBest Practice & Research Clinical Gastroenterology, 2003
- Selected loss of tolerance evidenced by Crohn's disease–associated immune responses to auto- and microbial antigensGastroenterology, 2002
- Genetic and Environmental Context Determines the Course of Colitis Developing in IL–10-Deficient MiceInflammatory Bowel Diseases, 2002
- Preliminary Study of Ciprofloxacin in Active Crohn's DiseaseInflammatory Bowel Diseases, 2002
- Long-term treatment of ulcerative colitis with ciprofloxacin: A prospective, double-blind, placebo-controlled studyGastroenterology, 1998
- Early lesions of recurrent Crohn's disease caused by infusion of intestinal contents in excluded ileumPublished by Elsevier ,1998
- Interleukin-10-deficient mice develop chronic enterocolitisCell, 1993